Format

Send to

Choose Destination
Ann Oncol. 2012 Jun;23(6):1601-7. doi: 10.1093/annonc/mdr485. Epub 2011 Oct 29.

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.

Author information

1
Department of Medical Oncology, Institut BergoniƩ, Bordeaux, France. italiano@bergonie.org

Abstract

BACKGROUND:

Data regarding the role of systemic therapy in patients with advanced well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) are limited.

METHODS:

From 2000 to 2010, 208 patients with advanced WDLPS/DDLPS received chemotherapy in 11 participating institutions. Clinical and pathological data were collected by reviewing medical records.

RESULTS:

Median age was 63 years (range 32-84). Combination chemotherapy was delivered in 85 cases (41%) and single agent in 123 cases (59%), respectively. One hundred and seventy-one patients (82%) received an anthracycline-containing regimen. Using RECIST, objective response was observed in 21 patients (12%), all treated with anthracyclines. Median progression-free survival (PFS) was 4.6 months [95% confidence interval (CI) 3.3-5.9]. On multivariate analysis, age and performance status (PS) were the sole factors significantly associated with poor PFS. Median overall survival (OS) was 15.2 months (95% CI 11.8 -18.7). On multivariate analysis, grade and PS were the sole factors significantly associated with OS.

CONCLUSIONS:

Chemotherapy was associated with clinical benefit in 46% of patients with advanced WDLPS/DDLPS. OS remains poor, even though visceral metastatic disease is less frequent than in other sarcomas.

PMID:
22039081
DOI:
10.1093/annonc/mdr485
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center